Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
100 participants
OBSERVATIONAL
2025-03-01
2025-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Maternal Cortisol Levels on Fetal Heart Rate Patterns
NCT05503433
Prognosis in Pregnant With COVID-19
NCT04409249
The Heart Outcomes in Pregnancy Expectations for Mom and Baby Study
NCT06517628
Pregnancy in GUCH Patients
NCT06574386
Metals and in Fetal Growth Restriction
NCT04394611
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Singleton uncomplicated pregnancies with at least 10 days of fasting.
Pregnant women who present for routine antenatal follow-up between 24-34 weeks of gestation.
All singleton uncomplicated pregnancies that present to our hospital for routine antenatal follow-up between 24-34 weeks of gestation will be included in this study.
The control group will consist of healthy pregnant women who do not fast, with singleton uncomplicat
Pregnant women who present for routine antenatal follow-up between 24-34 weeks of gestation.
All singleton uncomplicated pregnancies that present to our hospital for routine antenatal follow-up between 24-34 weeks of gestation will be included in this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pregnant women who present for routine antenatal follow-up between 24-34 weeks of gestation.
All singleton uncomplicated pregnancies that present to our hospital for routine antenatal follow-up between 24-34 weeks of gestation will be included in this study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Present for routine antenatal follow-up between 24-34 weeks of gestation
Exclusion Criteria
* Premature rupture of membranes
* Chorioamnionitis
* Placental abruption
* Severe fetal growth restriction
* Congenital fetal anomalies
* Preeclampsia
* Oligohydramnios
* Maternal diabetes -Conditions where fasting is contraindicated for the mother. -
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanliurfa Education and Research Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sanliurfa Education and Research Hospital
Sanliurfa, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ŞEAH/fasting card
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.